- Home
- CNTB
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 90.3M | IPO Year: | 2021 |
| Target Price: | $7.50 | AVG Volume (30 days): | 88.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.23 - $2.20 | Next Earning Date: | 11-13-2025 |
| Revenue: | $1,965,000 | Revenue Growth: | -91.85% |
| Revenue Growth (this year): | -99.94% | Revenue Growth (next year): | 453067.90% |
Latest Connect Biopharma Holdings Limited News
CNTB Breaking Stock News: Dive into CNTB Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 months ago
3 Promising Penny Stocks With Market Caps Over $10M
GlobeNewswire
4 months ago
Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
MT Newswires
4 months ago
Connect Biopharma Files $300 Million Mixed Shelf
GlobeNewswire
4 months ago
Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
GlobeNewswire
4 months ago
Connect Biopharma to Present at Two Upcoming Investor Conferences in June
GlobeNewswire
5 months ago
Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference
GlobeNewswire
5 months ago
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
5 months ago
Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
Compare CNTB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNTB Connect Biopharma Holdings Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.